Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Christopher Raymond is an analyst at Piper Sandler. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/07/2024
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 07/02/2024 | ABBV | Buy Now | AbbVie | $166.70 | 13.98% | $190 → $190 | Maintains | Overweight | Get Alert |
| 07/01/2024 | TSHA | Buy Now | Taysha Gene Therapies | $2.23 | 213.9% | $9 → $7 | Maintains | Overweight | Get Alert |
| 06/18/2024 | ABBV | Buy Now | AbbVie | $166.70 | 13.98% | $185 → $190 | Maintains | Overweight | Get Alert |
| 05/24/2024 | ARDX | Buy Now | Ardelyx | $5.46 | 174.73% | $15 → $15 | Maintains | Overweight | Get Alert |
| 05/07/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $481.89 | -5.37% | $450 → $456 | Maintains | Overweight | Get Alert |
| 05/03/2024 | BPMC | Buy Now | Blueprint Medicines | $116.32 | -10.59% | $78 → $104 | Maintains | Neutral | Get Alert |
| 04/29/2024 | ABVX | Buy Now | Abivax | $13.57 | 209.51% | → $42 | Initiates | → Overweight | Get Alert |
| 04/09/2024 | TSHA | Buy Now | Taysha Gene Therapies | $2.23 | 303.59% | → $9 | Initiates | → Overweight | Get Alert |
| 04/02/2024 | QTTB | Buy Now | Q32 Bio | $19.00 | 136.84% | → $45 | Initiates | → Overweight | Get Alert |
| 03/08/2024 | ALXO | Buy Now | ALX Oncology Holdings | $5.64 | 272.34% | $11 → $21 | Maintains | Overweight | Get Alert |
| 02/23/2024 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.68 | 29.41% | $115 → $107 | Maintains | Overweight | Get Alert |
| 02/23/2024 | ARDX | Buy Now | Ardelyx | $5.46 | 174.73% | $12 → $15 | Maintains | Overweight | Get Alert |
| 02/14/2024 | BIIB | Buy Now | Biogen | $228.07 | 42.5% | $350 → $325 | Maintains | Overweight | Get Alert |
| 12/22/2023 | ALVR | Buy Now | AlloVir | $0.76 | 97.6% | $27 → $1.5 | Downgrade | Overweight → Neutral | Get Alert |
| 11/15/2023 | BHVN | Buy Now | Biohaven | $34.50 | 4.35% | $29 → $36 | Maintains | Overweight | Get Alert |
| 11/03/2023 | KPTI | Buy Now | Karyopharm Therapeutics | $0.79 | 532.83% | $7 → $5 | Maintains | Overweight | Get Alert |
| 11/03/2023 | REGN | Buy Now | Regeneron Pharmaceuticals | $1.05K | -14.94% | $885 → $895 | Maintains | Overweight | Get Alert |
| 11/02/2023 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.68 | 39.09% | $125 → $115 | Maintains | Overweight | Get Alert |
| 10/30/2023 | DCPH | Buy Now | Deciphera Pharmaceuticals | — | — | $18 → $23 | Upgrade | Neutral → Overweight | Get Alert |
| 10/25/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $41.49 | 213.33% | $135 → $130 | Maintains | Overweight | Get Alert |
| 10/11/2023 | ALXO | Buy Now | ALX Oncology Holdings | $5.64 | 95.04% | $8 → $11 | Maintains | Overweight | Get Alert |
| 09/28/2023 | IOBT | Buy Now | IO Biotech | $1.22 | 719.67% | → $10 | Initiates | → Overweight | Get Alert |
| 09/19/2023 | KNTE | Buy Now | Kinnate Biopharma | — | — | $20 → $4 | Downgrade | Overweight → Neutral | Get Alert |
| 08/11/2023 | ALXO | Buy Now | ALX Oncology Holdings | $5.64 | 41.84% | $48 → $8 | Maintains | Overweight | Get Alert |
| 08/03/2023 | KPTI | Buy Now | Karyopharm Therapeutics | $0.79 | 785.96% | $8 → $7 | Maintains | Overweight | Get Alert |
| 07/28/2023 | ABBV | Buy Now | AbbVie | $166.70 | 1.98% | $163 → $170 | Maintains | Overweight | Get Alert |
| 06/12/2023 | COGT | Buy Now | Cogent Biosciences | $8.82 | 149.43% | → $22 | Maintains | Overweight | Get Alert |
| 06/01/2023 | BIIB | Buy Now | Biogen | $228.07 | 57.85% | $346 → $360 | Maintains | Overweight | Get Alert |
| 05/31/2023 | AKBA | Buy Now | Akebia Therapeutics | $0.95 | 321.05% | $2 → $4 | Upgrade | Neutral → Overweight | Get Alert |
| 05/23/2023 | VECT | Buy Now | VectivBio Holding | — | — | $25 → $17 | Downgrade | Overweight → Neutral | Get Alert |
| 05/12/2023 | MGTX | Buy Now | MeiraGTx Hldgs | $4.09 | 511.25% | $26 → $25 | Maintains | Overweight | Get Alert |
| 05/04/2023 | VRTX | Buy Now | Vertex Pharmaceuticals | $481.89 | -20.11% | → $385 | Assumes | → Overweight | Get Alert |
| 04/28/2023 | AMGN | Buy Now | Amgen | $311.46 | -7.53% | $293 → $288 | Maintains | Overweight | Get Alert |
| 04/27/2023 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.68 | 51.19% | $128 → $125 | Maintains | Overweight | Get Alert |
| 04/17/2023 | BIIB | Buy Now | Biogen | $228.07 | 51.71% | $280 → $346 | Upgrade | Neutral → Overweight | Get Alert |
| 02/10/2023 | ABBV | Buy Now | AbbVie | $166.70 | -2.22% | $157 → $163 | Maintains | Overweight | Get Alert |
| 02/03/2023 | AGIO | Buy Now | Agios Pharmaceuticals | $41.19 | -0.46% | → $41 | Initiates | → Overweight | Get Alert |
| 01/19/2023 | AMGN | Buy Now | Amgen | $311.46 | -5.93% | $299 → $293 | Maintains | Overweight | Get Alert |
| 01/19/2023 | KPTI | Buy Now | Karyopharm Therapeutics | $0.79 | 912.53% | → $8 | Initiates | → Overweight | Get Alert |
| 01/17/2023 | ABBV | Buy Now | AbbVie | $166.70 | -5.82% | $155 → $157 | Maintains | Overweight | Get Alert |
| 12/13/2022 | AMGN | Buy Now | Amgen | $311.46 | -4% | $297 → $299 | Maintains | Overweight | Get Alert |
| 11/17/2022 | ARDX | Buy Now | Ardelyx | $5.46 | 46.52% | $3 → $8 | Upgrade | Neutral → Overweight | Get Alert |
| 11/04/2022 | AMGN | Buy Now | Amgen | $311.46 | -10.74% | $265 → $278 | Maintains | Overweight | Get Alert |
| 11/04/2022 | REGN | Buy Now | Regeneron Pharmaceuticals | $1.05K | -27.3% | $775 → $765 | Maintains | Overweight | Get Alert |
| 10/26/2022 | BHVN | Buy Now | Biohaven | $34.50 | -39.13% | $23 → $21 | Maintains | Overweight | Get Alert |
| 10/13/2022 | OTIC | Buy Now | Otonomy | — | — | $3 → $0.5 | Downgrade | Overweight → Neutral | Get Alert |
| 10/12/2022 | BHVN | Buy Now | Biohaven | $34.50 | -33.33% | → $23 | Initiates | → Overweight | Get Alert |
| 09/28/2022 | BIIB | Buy Now | Biogen | $228.07 | 22.77% | $200 → $280 | Maintains | Neutral | Get Alert |
| 09/13/2022 | REGN | Buy Now | Regeneron Pharmaceuticals | $1.05K | -26.35% | $692 → $775 | Maintains | Overweight | Get Alert |
| 08/19/2022 | BHVN | Buy Now | Biohaven | $34.50 | — | — | Downgrade | Overweight → Neutral | Get Alert |
| 08/12/2022 | APTX | Buy Now | Aptinyx | $0.10 | 1983.33% | $6 → $2 | Downgrade | Overweight → Neutral | Get Alert |
| 08/09/2022 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.68 | 54.81% | $125 → $128 | Maintains | Overweight | Get Alert |
| 08/05/2022 | AMGN | Buy Now | Amgen | $311.46 | -14.92% | $260 → $265 | Maintains | Overweight | Get Alert |
| 08/01/2022 | ABBV | Buy Now | AbbVie | $166.70 | -7.02% | $160 → $155 | Maintains | Overweight | Get Alert |
| 07/29/2022 | RARE | Buy Now | Ultragenyx Pharmaceutical | $41.49 | 213.33% | $135 → $130 | Maintains | Overweight | Get Alert |
| 07/26/2022 | ONON | Buy Now | On Holding | $37.89 | -26.1% | → $28 | Initiates | → Overweight | Get Alert |
| 07/01/2022 | VECT | Buy Now | VectivBio Holding | — | — | → $23 | Initiates | → Overweight | Get Alert |
| 05/19/2022 | RARE | Buy Now | Ultragenyx Pharmaceutical | $41.49 | 225.38% | $170 → $135 | Maintains | Overweight | Get Alert |
| 05/19/2022 | ONCR | Buy Now | Oncorus | $0.13 | 9423.81% | $40 → $12 | Maintains | Overweight | Get Alert |
| 05/19/2022 | KNTE | Buy Now | Kinnate Biopharma | — | — | $52 → $30 | Maintains | Overweight | Get Alert |
| 05/19/2022 | GRAY | Buy Now | Graybug Vision | — | — | $56 → $28 | Maintains | Neutral | Get Alert |
| 05/19/2022 | BPMC | Buy Now | Blueprint Medicines | $116.32 | -44.12% | $84 → $65 | Maintains | Neutral | Get Alert |
| 05/19/2022 | ARDX | Buy Now | Ardelyx | $5.46 | -45.05% | $4 → $3 | Maintains | Neutral | Get Alert |
| 05/19/2022 | APTX | Buy Now | Aptinyx | $0.10 | 6150% | $10 → $6 | Maintains | Overweight | Get Alert |
| 05/19/2022 | ALXO | Buy Now | ALX Oncology Holdings | $5.64 | 751.06% | $70 → $48 | Maintains | Overweight | Get Alert |
| 05/19/2022 | ALVR | Buy Now | AlloVir | $0.76 | 4378.99% | $55 → $34 | Maintains | Overweight | Get Alert |
| 04/28/2022 | AMGN | Buy Now | Amgen | $311.46 | -16.52% | $255 → $260 | Maintains | Overweight | Get Alert |
| 03/31/2022 | AKBA | Buy Now | Akebia Therapeutics | $0.95 | 110.53% | $8 → $2 | Downgrade | Overweight → Neutral | Get Alert |
| 02/24/2022 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.68 | 51.19% | $121 → $125 | Maintains | Overweight | Get Alert |
| 01/18/2022 | ABBV | Buy Now | AbbVie | $166.70 | -4.02% | → $160 | Reiterates | → Overweight | Get Alert |
| 01/12/2022 | BIIB | Buy Now | Biogen | $228.07 | -5.29% | $362 → $216 | Downgrade | Overweight → Neutral | Get Alert |
| 01/03/2022 | ABBV | Buy Now | AbbVie | $166.70 | -4.02% | $129 → $160 | Maintains | Overweight | Get Alert |
| 11/01/2021 | ABBV | Buy Now | AbbVie | $166.70 | -22.62% | $124 → $129 | Maintains | Overweight | Get Alert |
| 03/13/2020 | INO | Buy Now | Inovio Pharmaceuticals | $8.46 | -5.44% | → $96 | Downgrade | Overweight → Neutral | Get Alert |
| 01/03/2020 | INO | Buy Now | Inovio Pharmaceuticals | $8.46 | -5.44% | $120 → $96 | Maintains | Overweight | Get Alert |
